Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 18;327(3):279-281.
doi: 10.1001/jama.2021.21921.

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals

Affiliations

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals

Brian Grunau et al. JAMA. .

Abstract

This study investigates the immunogenicity of extended mRNA vaccine dosing intervals.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Comparison of Serological Outcomes in Paramedics Who Received Short (≤28 Days) vs Medium (42-49 Days) mRNA Vaccine Dosing Intervals
The solid lines indicate the geometric mean. P values were derived from the Wilcoxon matched-pair signed rank test. A, Reciprocal of live viral Wuhan strain neutralization titers, expressed as highest serum dilution able to block viral cytotoxicity (geometric mean, 54.6 [geometric SD {GSD}, 3.0] for the short group vs 230.8 [GSD, 2.0] for the medium group). The dashed line indicates the lower limit of detection with values below set at 1:4. B, The antibody IgG concentration for the multiplex spike was 87 292 arbitrary units (AU)/mL (SD, 5.4 AU/mL) for the short group vs 163 167 AU/mL (SD, 2.2 AU/mL) for the medium group and for the receptor-binding domain (RBD) was 51 753 AU/mL (SD, 5.3 AU/mL) for the short group vs 128 987 U/mL (SD, 2.3 U/mL) for the medium group. C, Inhibition of angiotensin-converting enzyme 2 (ACE-2) binding to the SARS-CoV-2 receptor-binding domain for the Wuhan strain was 24.0 U/mL (SD, 1.9 U/mL) for the short group vs 31.9 U/mL (SD, 2.4 U/mL) for the medium group; for the Delta variant it was 8.64 U/mL (SD, 2.1 U/mL) for the short group vs 22.3 U/mL (SD, 2.0 U/mL) for the medium group.
Figure 2.
Figure 2.. Comparison of Serological Outcomes in Paramedics Who Received Short (≤36 Days) vs Long (100-120 Days) mRNA Vaccine Dosing Intervals
The solid lines indicate the geometric mean. P values were derived from the Wilcoxon matched-pair signed rank test. A, Reciprocal of live viral Wuhan strain neutralization titers, expressed as highest serum dilution able to block viral cytotoxicity (geometric mean, 41.8 [geometric SD {GSD}, 2.8] for the short group vs geometric mean, 302.3 [GSD, 2.4] for the long group). The dashed line indicates the lower limit of detection with values below set at 1:4. B, The antibody IgG concentration for the multiplex spike was 45 155 arbitrary units (AU)/mL (SD, 2.3 AU/mL) for the short group vs 129 299 AU/mL (SD, 2.8 AU/mL) for the long group. The receptor-binding domain (RBD) was 22 071 AU/L (SD, 2.4 AU/L) vs 66 022 AU/L (SD, 2.9 AU/L). C, Inhibition of angiotensin-converting enzyme 2 (ACE-2) binding to SARS-CoV-2 receptor binding domain for the Wuhan strain was 7.9 U/mL (SD,1.6 U/mL) vs 26.8 U/mL (SD, 2.9 U/mL) and for the Delta variant, 2.7 U/mL (SD, 1.5 U/mL) vs 8.7 U/mL (Sd, 2.4 U/mL).

References

    1. Centers for Disease Control and Prevention (CDC) . COVID-19. Accessed August 11, 2021. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-v...
    1. Voysey M, Costa Clemens SA, Madhi SA, et al. ; Oxford COVID Vaccine Trial Group . Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881-891. doi:10.1016/S0140-6736(21)00432-3 - DOI - PMC - PubMed
    1. Wahl M, Hermodsson S, Iwarson S. Hepatitis B vaccination with short dose intervals—a possible alternative for post-exposure prophylaxis? Infection. 1988;16(4):229-232. doi:10.1007/BF01650758 - DOI - PubMed
    1. Romero-Brufau S, Chopra A, Ryu AJ, et al. . Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study. BMJ. 2021;373(May):n1087. doi:10.1136/bmj.n1087 - DOI - PMC - PubMed
    1. Moghadas SM, Vilches TN, Zhang K, et al. . Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLoS Biol. 2021;19(4):e3001211. doi:10.1371/journal.pbio.3001211 - DOI - PMC - PubMed

Publication types

Supplementary concepts